Monitoring Milestones in Patients With Chronic Myeloid Leukemia

Slides:

Advertisements

Similar presentations

Dr N M Butt Consultant Haematologist

Advertisements

The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.

Chronic Myeloid Leukemia: Treatment Success and Milestones

Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.

OHSU Updates in Hematology and Breast Cancer Conference CML ASH Update Michael J. Mauro, MD.

DR Discontinuation of second generation tyrosine kinase inhibitors CML and MPDs UK national meeting Newcastle, March 1 st, 2013 Dr Delphine Rea Service.

Case based discussion Pankaj Malhotra PGIMER, Chandigarh, India.

Final Study Results of the Phase III Dasatinib versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA )1.

Stopping TKI treatment in CML: Who and when

Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M. Kantarjian, MD Chairman; Professor, Department of Leukemia.

1 Rea D et al. Proc ASH 2014;Abstract 811.

Copyright © 2011 Research To Practice. All rights reserved. Interest in Topics Related to the Treatment of Patients with CML (Percent Responding 9 or 10)

Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.

Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine.

Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Updated Results of the STIM 1 Discontinuation.

CML in China Qian Jiang, MD Peking University People's Hospital, Peking University Institute of Hematology

ENESTnd Update: Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and the Impact.

Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.

David Marin, Imperial College London Early molecular prediction of response to TKI.

Current use of imatinib in the treatment of chronic myeloid leukaemia Michael O’Dwyer Haematologica March 2003.

ENESTnd 24-Month Update: Continued Superiority of Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.

Questions to the Committee. Question 1. The Agency has accepted durable responses in hematologic malignancies for approval for both chronic leukemias.

Early Molecular and Cytogenic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML) Hanfstein B.

Treatment of CML. Goal of Therapy Complete molecular remission and cure – Achieve prolonged, durable, nonneoplastic, nonclonal hematopoiesis, – Eradication.

Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.

Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib,

Switching to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Cytogenetic Response on Imatinib: Results from the LASOR.

A Pivotal Phase 2 Trial of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR ‐ ABL Mutation:

Nilotinib versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP):

Dasatinib or Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Two-Year Follow-Up from DASISION Kantarjian H et al.

Update on Approved TKIs Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas.

The Challenge of Monitoring CML When Resources Are Limited Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center.

Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response New Findings in Hematology: Independent Conference.

HOW TO TREAT FIRST LINE FAILURE?

Shah N et al. Proc ASH 2010;Abstract 206.

Soverini S et al. Proc ASH 2015;Abstract 346.

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology

Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Clinical Focus: Options for Treatment-Resistant or Treatment-Intolerant.

Great Debates and Updates in Hematologic Malignancies 2014

Ellen K. Ritchie Clinical Director, Richard T. Silver MPN Center

The Nurse View Key Insights Along the CML Continuum

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Resistant CML: Understanding the Science to Change Outcomes

Great Debates and Updates in Hematologic Malignancies 2014

Imatinib – where are we now. What about generic imatinib

Chronic Myelogenous Leukemia Diagnosis and Treatment

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Advances in Myeloid Malignancies

Luis A. Carvajal, Ulrich Steidl Cell Stem Cell

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients.

Navigating New Oral Treatment Algorithms in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Chronic Myeloid Leukemia Challenge

Crossover for pts meeting ELN 2013 failure criteria

Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Pradnya Chopade, Luke P. Akard Clinical Lymphoma, Myeloma and Leukemia

Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy.

1Kantarjian HM et al. Lancet Oncol 2011;12:

Branford S et al. Proc ASH 2013;Abstract 254.

Leber B et al. Proc ASH 2013;Abstract 94.

The Changing Goals of CML Therapy

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova

The Pathway to Progress Against Chronic Myelogenous Leukemia.

Presentation transcript:

Monitoring Milestones in Patients With Chronic Myeloid Leukemia

Activity Goal

Treatment Milestones

Workup: Patient Newly Diagnosed in Chronic Phase

Definition of Response in CML

Definition of Response in CML (cont)

Response Milestones: Frontline Imatinib in Chronic Phase CML

Faster Responses With Nilotinib and Dasatinib

Prediction of Outcome Based on the 3-month Time Point

BCR-ABL/ABL < 10% by IS at 3 Months Predicts Outcome

What Are the Options When the 3-month Time Point Has NOT Been Reached?

At 3 Months, BCR-ABL of ≥ 10% IS Identifies High-Risk Patients

Retrospective Analysis of CML Study IV MMR and CCyR at 3 Months

Considerations for the 3-month Time Point

Conclusions

Monitoring at the 6-Month Time Point

Monitoring at the 6-month Time Point

Rise and Fall of BCR-ABL Transcript Levels With Imatinib Dosing

Retrospective Analysis of CML Study IV MMR and CCyR at 6 Months

Monitoring at the 12-Month Time Point

12-month Follow-up

12-month Follow-up (cont)

12-month Follow-up (cont)

12-month Follow-up: Relapse

Algorithm for Modulating Risk Factors

BCR-ABL KD Mutations Before and After Imatinib Therapy

Conclusions

Monitoring Patients at the 18-Month Time Point

Monitoring at the 18-month Time Point

Event-free Survival by Response

Monitoring at the 18-month Time Point

Treating Patients With Mutations in the Second Linea,b

Results With Second-/Third-Generation TKI After Imatinib Failure/Resistance

Cytogenetic Relapse at 18 months

Best Molecular Response

Thank you for participating in this activity.